Loading
Life sciences · Journal article
Cureus · October 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metastatic prostate cancer is a leading cause of cancer-related morbidity and mortality.Androgen deprivation therapy (ADT) remains the foundation of systemic treatment, with novel androgen receptor inhibitors such as apalutamide increasingly used in patients with metastatic hormone-sensitive prostate cancer (mHSPC).Apalutamide is generally well tolerated.Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is not recognized as an established side effect of apalutamide.We report the case of a man in his seventies who was initiated on apalutamide for mHSPC.Ten days after initiation, he developed a widespread maculopapular rash accompanied by biochemical abnormalities.Clinical assessment suggested a diagnosis of DRESS syndrome, most consistent with the criteria of Bocquet et al.The patient was managed with immediate discontinuation of apalutamide and initiation of high-dose systemic corticosteroids.He improved clinically and biochemically and subsequently transitioned to enzalutamide.This case highlights the importance of recognizing rare but potentially life-threatening adverse reactions associated with apalutamide.